Integrated Solution Provider for Pharmaceutical Industry “From Upstream to Downstream”
Updated June 2016
Global Based One-stop Shop for Pharmaceutical Industry
The pharmaceutical industry has evolved remarkably since the latter half of the 20th century, so much so that some people are calling the 21st century “the century of pharmaceuticals.” The development of new drugs and the sourcing of materials for drugs are now conducted beyond countries and pharmaceutical companies are operated in a global basis.
Engaging together with its subsidiaries in its pharmaceuticals business, Summit Pharmaceuticals International Corporation (SPI), Summit Pharmaceuticals Europe(SPE) and Summit Pharmaceuticals China(SPC), Sumitomo Corporation offers comprehensive support to players in both the upstream and downstream segments of the pharmaceutical industry. We not only support the R&D of but also supply materials for new drugs and generic drugs by taking advantage of its long and broad experience and unique global structure as a general trading company. Through these activities, Sumitomo Corporation broadly contributes to the improvement of people’s quality of life worldwide.
For the discovery and clinical trial stages, we do investments and lending in pharmaceutical ventures and provide agency services for research alliances and licenses. For later developmental and commercial stages, we select appropriate suppliers from manufacturers in Japan, Europe, India, China, etc. andprovide raw materials, active pharmaceutical ingredients (APIs), and final products to pharmaceutical companies. We also help foreign manufacturers to apply for the registrations like Foreign Manufacturer Accreditation(FMA) and Master File(MF) in Japan. In addition, API Laboratory (Kawasaki City) has been established to ensure the supply of high-quality APIsconforming to specifications, by carrying out quality analysis by its own staffs.
Staffs at API Laboratory who analyze API quality to check conformity with specifications
Contribution to Drug Discovery
With the phenomenal development of life sciences research, the roles played by drug discovery instruments, bio-resource materials, and drug discovery technology have become increasingly important. SPI distributes several products and provides related services in drug discover area.
In the area of drug discovery instruments, SPI provides in vivo imaging equipments that allow non-invasive monitoring ( that is not damaging to the living body) of the progress and healing process of disease. SPI’s Support Center in Yokohama offers comprehensive customer support, including instrument demonstration, quality inspection, repair, maintenance, and consultation on instrument applications. SPI also holds the In Vivo Imaging Forum , in which leading scientists give presentations on the latest uses of the instruments for customers. Having been held 10 times, the forum is attracting increasing attention.
In the area of drug discovery support, SPI offers services that meet frontline needs, which include intermediating for new drug licenses and research alliances as well as providing bio-resource materials, such as cell lines and genetic material for research in Japan. Meanwhile, over the 30-plus years since it entered the distribution business of bio-resource materials, SPI has enhanced the lineups of gene vectors, cell lines with genetic mutations, iPS cell-related materials and so on. In recent years, SPI has also begun distribution of high-quality human tissue samples stored after removed by surgery to research together with information on the pre- and post-operation history of disease and treatment.
SPI has also launched a new initiative in the area of biomarkers, which are used to measure the specific compounds in blood, urine, etc.and to diagnose the state of a particular disease or some other physiological condition. In order to extend comprehensive support for research and development in the pharmaceutical industry, SPI provides multifaceted services by collaborating with biotech companies and research institutions in and outside Japan and combining human tissue samples with biomarker research. As a member of the Sumitomo Corporation Group, SPI aims to support the biotech and pharmaceutical industries, with its series of integrated R&D support services.
In Vivo Imaging Forum 2015
Supporting the Popularization of Generic Drugs
The term “generic drug” is now in common. In fact, many people may have had the experience of being asked by their prescribing physician whether or not they would prefer a generic drug. So what are generic drugs? When patents for new drugs expire, drugs made of the same components and with the same efficacy are put on the market. These are called generic drugs. Their advantage is that they can be offered at lower prices because they do not entail development costs.
SPI supplies APIs to generic drug manufacturers. Taking advantages of the global network of the Sumitomo Corporation Group, SPI selects, from all over the world, suppliers of high-quality APIs that demonstrate strong price competitiveness. It then conducts specification setting and quality testing of these ingredients at its API Laboratory, which is equipped with cutting-edge analyzers. By ensuring a stable supply of competitive, quality-controlled APIs, SPI helps reduce the cost of generic drugs as well as achieve their stable supply.
The market share of generic drugs in volume accounted for around 47% of Japan’s pharmaceutical industry in fiscal 2013. The Japanese government promotes the use of generic drugs with the ambitious goal of boosting their share to 80% as early as possible before 2020.
By supporting the popularization of generic drugs, the Sumitomo Corporation Group not only contributes to reducing the economic burden on individual patients but also helps control medical healthcare expenses in Japan as a whole.
Inside the API Laboratory in Kawasaki. The popularization of generic drugs leads to the creation and promotion of revolutionary new drugs.
Providing Emerging Countries with the Access to Innovative Drugs
The Chinese pharmaceutical market has reportedly outperformed Japan to become the second largest in the world, and China and other emerging markets are expected to further expand in the future. Sumitomo Corporation intends to place more emphasis on expanding its business in these emerging pharmaceuticals markets.
Like advanced countries, developing countries have an urgent need to improve the healthcare environment as the economy develops and living conditions improve. Sumitomo Corporation will be there every step of the way, contributing to the enhancement of people’s quality of life in these countries under our global integrated service for the pharmaceutical industry, as well as via C&O Pharmaceutical Technology Holdings Ltd., a Chinese pharmaceutical company based in China in which Sumitomo Corporation took a stake in 2010.
The BIO International Conference, one of the world’s largest exhibitions of new drugs and biotechnology, is held annually in the United States. A number of companies from emerging nations exhibit their products.
- Mineral Resources, Energy, Chemical & Electronics Business Unit
- Japan / U.S.A. / China
- Chemical & Electronics
- Business Unit
- Product or Service